Open access
Open access
Powered by Google Translator Translator

Allergy & Immunology

Perspective | Should People With Immune Problems Get Third Vaccine Doses?

8 Jul, 2021 | 09:07h | UTC

Should People With Immune Problems Get Third Vaccine Doses? – The New York Times (a few articles per month are free)

Related: [Preprint] 3rd AstraZeneca shot gives strong immunity. AND Case series: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients.

 

Joint COVAX Statement on the Equal Recognition of Vaccines – COVAX urges all government authorities to recognize as fully vaccinated all people who have received COVID-19 vaccines that have been deemed safe and effective by WHO.

5 Jul, 2021 | 02:39h | UTC

Joint COVAX Statement on the Equal Recognition of Vaccines – World Health Organization

 

Commentary on Twitter (thread – click for more)

 

Opinion | Covid is a greater risk to young people than the vaccines.

5 Jul, 2021 | 02:34h | UTC

Covid Is a Greater Risk to Young People Than the Vaccines – The New York Times

Counterpoint: Weighing myocarditis cases, ACIP failed to balance the harms vs benefits of 2nd doses – by Wesley Pegden AND Vaccine-Induced Myocarditis Concerns Demand Respect, Not Absolutism – Medscape (free registration required)

 

Commentary on Twitter

 

Roundup on Covid vaccines | A Big Hit, A Big Miss, & Mixed Vaccine Schedules: The 18-Month Mark.

5 Jul, 2021 | 02:31h | UTC

A Big Hit, A Big Miss, & Mixed Vaccine Schedules: The 18-Month Mark – Absolutely Maybe Blog

 

Commentary on Twitter

https://twitter.com/hildabast/status/1411083833022181378

 

Why Covid-19 outbreaks in countries using Chinese vaccines don’t necessarily mean the shots have failed.

5 Jul, 2021 | 02:30h | UTC

Why Covid-19 outbreaks in countries using Chinese vaccines don’t necessarily mean the shots have failed – CNN

 

What are the Sinopharm and Sinovac vaccines? And how effective are they? Two experts explain.

5 Jul, 2021 | 02:28h | UTC

Related: What are the Sinopharm and Sinovac vaccines? And how effective are they? Two experts explain – The Conversation

 

Germany issues world’s strongest recommendation for mixing Covid-19 vaccines.

5 Jul, 2021 | 02:27h | UTC

Germany issues world’s strongest recommendation for mixing Covid-19 vaccines – CNN

Related: [Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

 

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

2 Jul, 2021 | 11:47h | UTC

Mixing Covid jabs has good immune response, study finds – BBC

Original study (preprint): Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine – SSRN Preprints with the Lancet

 

[Press release] J&J single-shot COVID-19 vaccine generates strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants.

2 Jul, 2021 | 11:38h | UTC

Press release: Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response

Commentary: J&J Covid Shot Neutralizes Delta Variant, Company Says – Bloomberg (a few articles per month are free)

 

RCT: Novavax vaccine conferred 89.7% protection against symptomatic SARS-CoV-2 infection and 100% protection against hospitalizations or deaths.

1 Jul, 2021 | 09:59h | UTC

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine – New England Journal of Medicine

Audio interview: Audio Interview: Another New Covid-19 Vaccine – New England Journal of Medicine

Related: Opinion | The mRNA vaccines are extraordinary, but Novavax is even better

 

Analysis: How long does covid-19 immunity last?

1 Jul, 2021 | 09:56h | UTC

How long does covid-19 immunity last? – The BMJ

 

Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms.

30 Jun, 2021 | 10:24h | UTC

Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms – Frontiers in Microbiology

 

Case Series: Myocarditis following immunization with mRNA COVID-19 vaccines.

30 Jun, 2021 | 10:22h | UTC

Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military – JAMA Cardiology

See also: Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination – JAMA Cardiology

Editorials: Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines AND Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis: The Vaccine Safety Surveillance System Is Working

Commentary: More Evidence Links Myocarditis to mRNA COVID-19 Vaccines – TCTMD

Related: CDC: mRNA vaccines are likely linked to cases of myocarditis and pericarditis – 1,226 cases of myocarditis or pericarditis have been reported mostly in people under 30.

 

Commentary on Twitter

 

Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta.

30 Jun, 2021 | 10:11h | UTC

Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta – The Conversation

Related: Effectiveness of COVID-19 vaccines against the B.1.617.2 variant – medRxiv

 

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

29 Jun, 2021 | 10:09h | UTC

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial – The Lancet Infectious Diseases

Invited commentary: COVID-19 vaccines for children younger than 12 years: are we ready? – The Lancet Infectious Diseases

 

Commentary on Twitter

 

SARS-CoV-2 mRNA vaccines induce persistent human germinal center responses, suggesting immunity will be long-lasting.

29 Jun, 2021 | 10:03h | UTC

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses – Nature

Commentaries: Immune response to FDA-approved vaccines is strong and potentially long-lasting – News Medical

Related: A long-term perspective on immunity to COVID – “Clinical studies now indicate that immunity will be long-lasting”.

 

Commentary on Twitter (thread – click for more)

 

Case report: Thrombosis with Thrombocytopenia After the Messenger RNA–1273 Vaccine.

29 Jun, 2021 | 10:07h | UTC

Thrombosis With Thrombocytopenia After the Messenger RNA–1273 Vaccine – Annals of Internal Medicine

Commentary: Expert reaction to case report of from the U.S. of thrombosis with thrombocytopenia after the Moderna mRNA vaccine – Science Media Centre

 

[Preprint] 3rd AstraZeneca shot gives strong immunity.

29 Jun, 2021 | 10:01h | UTC

Study: 3rd AstraZeneca shot gives strong immunity – Reuters

Original Study (preprint): Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222) – SSRN/The Lancet

 

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

28 Jun, 2021 | 10:01h | UTC

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial – The Lancet

Commentaries: Heterologous vaccine regimens against COVID-19 – The Lancet AND

 

Commentary on Twitter (thread – click for more)

 

RCT: Similar outcomes with mycophenolate mofetil vs. azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression.

29 Jun, 2021 | 09:50h | UTC

Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial – PLOS One

 

Perspective | Is one vaccine dose enough if you’ve had COVID? What the science says.

28 Jun, 2021 | 09:52h | UTC

Is one vaccine dose enough if you’ve had COVID? What the science says – Nature

Related: Another study shows a single dose of an mRNA vaccine has maximal effects in those with past infection.

 

Commentary on Twitter

 

[Preprint] Long Covid: Third of people infected have long term symptoms.

25 Jun, 2021 | 10:30h | UTC

Covid-19: Third of people infected have long term symptoms – The BMJ

Original study (preprint): Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people – Imperial College London

 

Long Covid: Half of young adults with COVID-19 have persistent symptoms 6 months after, study finds.

25 Jun, 2021 | 10:33h | UTC

Half of young adults with COVID-19 have persistent symptoms 6 months after, study finds – The University of Bergen

Original Study: Long COVID in a prospective cohort of home-isolated patients – Nature Medicine

 

Commentary on Twitter

 

Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients can improve the immunogenicity of the vaccine.

24 Jun, 2021 | 10:32h | UTC

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients – New England Journal of Medicine

 

Another study shows a single dose of an mRNA vaccine has maximal effects in those with past infection.

24 Jun, 2021 | 10:38h | UTC

Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses – ACS Nano

Related: France recommends single dose of vaccine if previous Covid infection detected. AND [Preprint] More data showing a single-dose SARS-CoV-2 mRNA vaccine may be enough in individuals with previous COVID-19. AND Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.